Similar anti-CD7 CAR T-cell products are being investigated for their ability to mediate lymphodepletion and myeloablation ahead of allogeneic (allo-) SCT, and have been utilised to treat AML exhibiting CD7 antigen expression [14]. The gene discussed is CD7; the disease is acute myeloid leukemia.